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The autoimmune basis of segmental vitiligo (SV) has only recently been recognized. Systemic
autoimmune diseases are less frequently associated compared to non-segmental vitiligo
(NSV), but localized skin disorders – in particular linear morphea – have been repeatedly
observed in patients with SV. The inflammatory response is documented on a clinical level
with cases displaying erythematous borders or a hypochromic stage, on a histopathological
level with predominantly CD8 lymphocytes migrating toward the basal layer and by flow
cytometry demonstrating the antimelanocyte specificity of these cytotoxic T cells. The
increased risk for halo naevi and NSV in these patients further underline the immune-
mediated mechanisms of SV. Nonetheless, the localized and unique distribution pattern
points to somatic mosaicism. This places SV in a category of similar diseases such as lichen
striatus, blaschkitis, linear lupus erythematosus, and linear scleroderma where an immune
reaction against genetically mutated skin cells is believed to be the underlying cause. All these
disorders are characterized by a young age of onset, a temporary disease activity with
spontaneous resolution, limited response to treatment, and often long-term sequelae.
Although challenging, genetic research proving this genetic mosaicism could offer crucial
insights into the pathogenesis of both segmental and non-segmental vitiligo.
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The prevalence of vitiligo is reported to be around 0.5-1% of the population, although remarkable
regional differences exist (1). Segmental vitiligo (SV) accounts for 5-16% of all vitiligo cases and has a
relatively equal gender distribution. However, some studies report a slight predominance of females (2,
3). SV has several unique characteristics compared to non-segmental vitiligo (NSV). SV usually involves
only one body area and displays a sharp demarcation around the midline of the body. It can develop at
all ages although a predominance around 4-10 years exists (4). Progressionmostly occurs in the first year
with a spontaneous stop of new depigmentations after 1.5-2 years in the majority of patients. In some
patients, SV stabilizes even after a few days (8/141; 16.7%) (5). However, this is not always the case as in
one study, 36.8% of patients still reported progression after 2 years (6). The development of SV areas on
opposite body sites has been termed bilateral SV. Mixed vitiligo is the concomitant presence of both SV
and NSV in the same patient (7). In contrast to NSV, poliosis is often visible at an early stage and far
more frequent compared to NSV. When examined in detail, almost all SV patients exhibit leukotrichia
(8). Itch might be an underrecognized symptom being present in 20% of SV patients (9).
Melanocytes carrying a mosaic mutation which elicits a targeted immune response are suspected as
the underlying cause of SV (10). Additionally, several other hypotheses have been put forward in anorg October 2020 | Volume 11 | Article 5684471
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mosaicism, and oxidative stress. In the last years, research suggests
that different theories likely play a combined role.
During the progressive phase, topical anti-inflammatory
treatments including corticoids or immunomodulators are
advised (11). UVB or excimer treatment can be initiated but
the repigmentation rates are lower compared to NSV (12).
Nonetheless, UVB/excimer therapy can be considered in
patients with recent disease onset or combined with pigment
cell transplantation. Shah et al. reported a 75% repigmentation in
78% of patients with 35.6% showing complete repigmentation
after excimer light combined with topical tacrolimus (13). Both
marginal and perifollicular repigmentation patterns can be
observed (14).AUTO-IMMUNITY IN SEGMENTAL
VITILIGO
NSV is characterized by multiple auto-immune disorders with
thyroid disease and alopecia areata being the most prevalent. The
rates of auto-immune disorders are higher in NSV compared to SV,
especially concerning thyroid disease (15). Lim et al. found positive
thyroid peroxidase antibodies in 24.7% of NSV patients while this
was only 15.1% in SV (16). A systematic review documented a
prevalence of thyroid disorders of 3/69 (4.3%) in SV which was not
increased compared to healthy controls (17). This underlines the
difference in pathogenesis between both disorders. While in NSV, a
genetic background of increased risk to autoimmunity has been
uncovered by genome-wide analyses [e.g. a major histocompatibility
complex (MHC) enhancer polymorphism], this is less expected in
its segmental counterpart (18). A relatively small whole-genome
expression study (20 SV; 20 NSV; 20 healthy controls) found more
differentially expressed genes involved in the adaptive immune
response in SV while in NSV regulation of the innate immune
response, B cell differentiation and activation was more prominent
(19). This suggests that the melanocyte immune response in SV is
more targeted and involves a narrower inflammatory activation
profile (e.g. less evidence for autophagy) compared to NSV. The
inflammatory response in SV is short-lived and localized, but
evidence for an immune-based cytotoxic destruction of SV
melanocytes is increasing. From a clinical perspective, 2 cases of
inflammatory SV have been reported (20–22). In a relatively small
study, immunohistochemistry revealed a lesional lymphocytic
infiltrate in 8/12 of progressing SV patients comparable to NSV
with a predominance of CD8+ T cells migrating toward the basal
layer. A non-significant increase in IFN-g was observed (23). In a
larger study (SV n = 50), histopathological inflammatory features
were noticed in 78% (38/50) of patients. In 42% (21/50), small
clusters of lymphocytes were found around melanocytes. In 36%
(18/50) of SV patients, a focal lichenoid inflammation was present
and in 22% (11/50) post-inflammatory changes were observed (24).
Our group analyzed the lymphocytic infiltrate in a progressive case
of SV more in-depth using HLA-peptide tetramers (MART-1,
tyrosinase, gp100). We discovered both in lesional and non-
lesional skin CD8 lymphocytes with a high production of IFN-gFrontiers in Immunology | www.frontiersin.org 2and TNF-a. An increased percentage of CD8 lymphocytes targeting
the melanocyte differentiation peptide gp100 was observed both in
lesional and non-lesional skin (25).
Nonetheless, this antimelanocyte-specific response can explain
why halo naevi can develop and why progression to NSV can occur.
Deregulation of chemotactic signals of CCL11, CCL17, CCL22,
CCL24, CCL27, CXCL10, and CXCL12 was found in SV which was
associated with a prominent inflammatory infiltrate. CD11c+
dendritic cells were abundantly present together with CD8 T cells
(26). In another study, no difference in lesional versus non-lesional
SV levels of sICAM-1 and GM-CSF was detected (n=16) (27).
However, this study did not specify whether it concerned stable or
progressive SV vitiligo lesions which might explain the lack of
difference in inflammatory markers. SV skin contains increased
epidermal oxidative stress (H2O2/ONOO(-)) (28). Similar to NSV,
increased levels of superoxide dismutase (SOD), decreased
antioxidative enzymes such as catalase, and increased lipid
peroxidation levels were found (29). Whether this concerns a
primary cause or a secondary phenomenon due to inflammation,
remains a topic of debate. Up till now, reproducible results of
effective SV treatment with antioxidants are lacking.
Poliosis is an important and early sign of SV. This indicates that
the immune-privileged environment around the hairs is less
protective in SV compared to NSV. As the reservoir of
melanocyte precursors around the hair bulb is often depleted in
SV, repigmentation is less impressive when phototherapy is initiated
(12). Several immune checkpoints [e.g. programmed death ligand-1
(PD-L1), indoleamine 2,3-dioxygenase (IDO)] have been found to
regulate the immune privilege of the hair follicle. Inhibition of these
factors by immunotherapy for melanoma results often in the
development of vitiligo-like lesions very similar to NSV (30, 31).
It is therefore plausible to speculate that SV is less dependent on
changes in factors regulating immune privilege compared to
NSV (32).
Mixed vitiligo has been reported in a subset of SV patients (7).
In our experience, depigmented areas are in the majority of
patients limited, but progression to extensive vitiligo vulgaris is
possible. Usually, SV precedes the development of NSV (7, 33).
Halo naevi are relatively frequent in SV although variable
percentages have been reported in the literature (5.3%-24.2%)
(34). The frequency strongly depends on the area of SV
involvement (trunk > face) (5). Halo naevi and leukotrichia are
strong predictors of progression to mixed vitiligo (OR= 24.8 and
25.7, respectively) (33). The presence of halo naevi in SV is
associated with a positive family history of vitiligo and thus
linked to the genetic background (33). Several theories for the
subsequent development of NSV can be proposed. Healthy
individuals carry circulating melanocyte-specific T cells with an
anergic phenotype (35). This cell population is believed to be a
protective mechanism against the development of melanoma
when the balance is shifted from anergic to active. Regulatory T
cells (Tregs) are implied in the maintenance of this anergic state.
During the pathogenesis of SV, these cells may become activated
by losing coinhibitory molecules [e.g. cytotoxic T lymphocyte
antigen-4 (CTLA-4)] and gaining a higher T cell receptor affinity.
This can lead to the active destruction of naevoid and epidermalOctober 2020 | Volume 11 | Article 568447
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NSV in genetically predisposed patients. Another mechanism
can be epitope spreading where immune cells involved in
targeting SV melanocytes acquire specificity for naevoid or
epidermal melanocytes.CASES OF SEGMENTAL VITILIGO
DISPLAYING ADDITIONAL
SKIN DISORDERS
Although the rate of autoimmune disorders is not markedly
increased in SV, some interesting cases have been described with
other inflammatory and non-inflammatory disorders co-occurring
at the same site (Table 1). A literature search was performed using
Embase and Pubmed databases from conception up to May 10,
2020. All original articles, reviews, and different types of articles
including letters to the editors, conference papers, and posters were
included. Embase was searched using the terms “segmental vitiligo”
OR “segmental vitiligo”/exp. Pubmed was searched using
“segmental vitiligo” [All fields] OR “segmental vitiligo” [Mesh].
All types of articles, in any language, were included. Articles without
full-text availability were excluded. Articles with both SV and NSV
were only included in case results on SV were described in detail.
The goal was to include all case reports mentioning comorbid
disorders in patients with SV or drug-induced SV. The literature
search was done by 2 independent reviewers (RS and MS) and was
uploaded with Zotero software. The data were extracted by RS.
Overlapping studies were excluded based on the author list
and content.
In total, 564 and 449 results were found for Embase and
Pubmed, respectively. For the Embase search, 3 duplicates were
removed based on the same content. Titles and abstracts of all
articles were screened. One case was excluded due to doubt about
the clinical diagnosis of segmental vitiligo based on the clinical
picture. Combining both searches, 38 reports could be included
describing patients with SV and a comorbid disorder comprising
21 patients with auto-immune disorders, 5 cases of drug-induced
vitiligo, 5 cases with benign or malignant pigment disorders, 3
cases with neurological disorders, and 6 other cases
A remarkable number of case-reports with morphea and
lichen sclerosus have been published (39, 40, 44, 70). 11
different reports were found which makes it by far the most
frequently observed comorbidity [57.1% (12/21 patients) of
reported patients with autoimmune comorbidities]. In most
cases, the morphea lesions affected the same body area as the
SV, although multifocal morphea was also documented (36–
46). Cases with lichen striatus are interesting because of the
striking similar pathogenesis (48) (Figure 1). A cytotoxic
lymphocyte attack against postzygotic mutant keratinocytes has
been proposed as the underlying mechanism of lichen striatus.
This inflammatory response is especially pronounced in the
basal and suprabasal layers which explains the development of
postlesional hypopigmentation (71). Interestingly, also other localized
skin disorders were reported in SV including segmental lichenFrontiers in Immunology | www.frontiersin.org 3planus, zosteriform lichen planus pigmentosus, lichen nitidus, and
linear psoriasis (48–52). While relatively common in NSV, alopecia
areata was only reported in 2 cases (10, 47).
Drug-induced SV is rare, especially infliximab is interesting given
the dual effect TNF-a inhibition exerts on NSV (53, 54). TNF-alpha
blockers are linked to the new development of NSV whereas also a
stabilizing effect on existing NSV has been found (72, 73). A 34-year
old patient with ulcerative colitis developed SV 4 months after
initiation of infliximab (54). Another 46-year old patient receiving
infliximab for rheumatoid arthritis developed SV after 2 months





Morphea en coup de sabre 22 Ubaldo et al. (36)
Circumscribed morphea 10 Lee et al. (37)
Morphea at same body area 10, 10 Dev et al. (38)
Morphea 10 Kim et al. (39)
Segmental morphea 18 Yadav P. et al. (40)
Morphea en coup de sabre 46 Janowska et al. (41)
Parry-Romberg syndrome 46 Wolek et al. (42)
Morphea en coup de sabre 9 Bowen et al. (43)
Lichen sclerosus 41 Weisberg et al. (44)
Linear morphea 21 Bonifati et al. (45)
Parry-Romberg syndrome 11 Creus et al. (46)
Other autoimmune diseases
Alopecia areata, segmental lichen
planus
12 Kumar et al. (47)
Lichen striatus 4, 5, 6 Correia et al. (48)
Zosteriform lichen planus
pigmentosus
22 Sawatkar et al. (49)
Linear psoriasis 47 Valbuena et al. (50)
Alopecia areata, psoriasis 25 van Geel et al. (10)
Lichen nitidus (and Down’s
syndrome)
4 Agarwal et al. (51)
Segmental lichen planus 14 Sardana et al. (52)
Drug-induced
Infliximab for rheumatoid arthritis 46 Carvalho et al. (53)
Infliximab for ulcerative colitis 34 Ryu et al. (54)
Immunotherapy for house dust mite 10 Shin et al. (55)
Isotretinoin 17 Avelar-Caggiano et al. (21)
Interferon alpha and ribavirin 60 Tinio et al. (56)
Co-occurring benign or malignant pigment conditions
Cerci et al. (57) 37 Metastatic melanoma
Tiwary et al. (58) 9 Segmental naevus spilus
Kuruvilla et al. (59) 10 Segmental lentiginosis
Luo et al. (60) 8 Naevus of ota
Hofmann et al. (61) 6 Congenital naevus
Linked neurologic disorders
Singh et al. (62) 13 Encephalitis
Yacubian et al. (63) 3 Rasmussen encephalitis
Jang et al. (64) 56 Schwannoma
Other
Utaş et al. (65) 14 Baboon syndrome
Rajashekar et al. (66) 20 Twenty nail dystrophy
Kandpur et al. (67) 14, 23 Twenty nail dystrophy
Muramatsu et al. (68) 22 Naevoid basal cell carcinoma
syndrome
Tay et al. (69) / Porencephaly, nasofrontal
mucoceles, hypertelorismOctober 2020 | Volume 11 | Article 568447
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trigger of NSV - induced SV in a patient with hepatitis C (56).
Besides halo naevi, other pigment disorders are rare in SV. Only
isolated reports of SV patients with co-existing segmental
lentiginosis, segmental naevus spilus, and a naevus of Ota were
found (58–61).
Overall, most co-occurring mosaic disorders in SV patients are
characterized by a cutaneous inflammation which may be triggered
by the immunologic events in active SV (or vice versa, the SV may
be induced by the other inflammatory mosaic disorder). Another
important group (e.g. segmental lentiginosis, neurologic disorders)
consists of genetic or non-genetic diseases affecting melanocytes or
their precursor cells.EVIDENCE OF SOMATIC MOSAICISM
The characteristic distribution patterns of SV suggest a genetically
mutated population of melanocytes which is targeted by a
cytotoxic cell response. Different patterns of segmental vitiligo in
the face and on the trunk have been detected and can easily be
recognized in clinical practice (74, 75). By comparing different
unilateral and localized skin disorders, we found that the SV
pattern does not follow a dermatomal distribution but displays a
unique distribution pattern that shares the largest similarity with
segmental lentiginosis, followed by epidermal naevus verrucosusFrontiers in Immunology | www.frontiersin.org 4(76). Due to the remarkable overlap with segmental lentiginosis,
the contribution of other skin cells such as keratinocytes, or
alterations in the dermis are less plausible in SV. Additionally,
segmental vitiligo follows the embryonal migration lines of
melanocyte precursors. During embryogenesis, precursors of
melanoblasts migrate from the neural crest in a dorsolateral
way. During this migration, an impressive number of cell
proliferations takes place enhancing the chance of genetic
mosaicism. Another subpopulation of adult melanocytes
originates from precursor cells with Schwan cell/melanoblast
potential that migrate on a ventrolateral pathway. In mice, 65%
of melanocytes of hair follicle melanocytes were linked to this
separate group of melanocyte progenitors (77, 78). This might
explain why long-lasting perifollicular repigmentation is
sometimes possible in SV (14). This reservoir of perifollicular
melanocytes and melanocyte precursors is however often not
spared after prolonged periods of disease activity and
phototherapy early in the disease (<6 months) gives better
results (12). Interestingly, the frequency of SV on the back is
lower compared to the lateral area, followed by the abdomen
which aligns nicely with the migration route of melanoblasts (76).
The temporary inflammation followed by a stable course in most
SV patients is a clear differentiating factor between SV and NSV.
This supports an inherent genetic defect carried by melanocytes in
the affected segment. After removal of the susceptible SV
melanocytes, the inflammation subsides. This is illustrated byA B C
FIGURE 1 | Segmental vitiligo, linear morphea, and lichen striatus are presumed to share a similar pathogenesis based on a genetic mosaicism causing an
inflammatory response. In segmental vitiligo (A), a CD8-dominant infiltrate around melanocytes is observed ultimately leading to melanocyte destruction. Linear
morphea (B) is characterized by dermal sclerosis and an inflammation of variable extent consisting of lymphocytes, plasma cells, and occasional eosinophils. Lichen
striatus (C) exhibits a focal lichenoid lymphocytic infiltrate with macrophages. Hyperparakeratosis, acanthosis, exocytosis, spongiosis, vacuolar interface dermatitis,
and colloid bodies can be observed.October 2020 | Volume 11 | Article 568447
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compared to NSV (79).NEUROGENIC THEORY
For many years, SV was described to follow a dermatomal
distribution and consequently, the involvement of neurogenic
factors was suspected. Several cases with encephalitis preceding
SV have been reported (62, 63). It should, however, be noted that
this is also the case for NSV (80). Especially in NSV, elevated levels
of neuropeptides [e.g. neuropeptide Y (NPY)] have been discovered.
This does not confirm the involvement of neurogenic mechanisms
as neuropeptides are also released following skin inflammation in
other skin diseases such as psoriasis (81). Nonetheless,
neuropeptides control regional skin immunity and some have
important effects on melanocytes [e.g. a melanocyte-stimulating
hormone (a-MSH)]. 2 cases of SV patient with schwannomas were
found. This offers however more a clue toward somatic mosaicism
given their common origin from the neural crest than an argument
for a neurogenic cause of SV (64). Schwann cells can even in vitro be
dedifferentiated to glia/melanocyte precursors illustrating their
common origin (82). A study including 76 patients with SV
found a slower nerve conduction velocity on the lesional side of
the body compared to the contralateral side which was more
pronounced in stable SV (83). Although the difference was small,
it could be shed new light on the neurogenic involvement in SV if
these results can be confirmed.FUTURE PERSPECTIVES
Overall, research on SV remains limited as only 4.8% of vitiligo
research discusses findings on SV on Pubmed. This is remarkable
as SV is likely to be a less multi genetic disorder compared to
NSV which might offer interesting information to the key factors
making melanocytes vulnerable for immune-based destruction.
The number of publications on SV is even declining in recent
years in contrast to the rising yearly numbers on NSV.
Based on previous research, an inflammatory response has been
proven in themajority of SV patients. The lack of markedly increased
rates of associated systemic autoimmune comorbidities highlights the
chance of a susceptible skin environment. As discussed above, the
distribution patterns of SV render genetic mosaicism is very likely.
This suggests that SV follows a similar pathogenesis compared to
lichen striatus, blaschkitis, linear morphea, and linear lupus
erythematosus. All these conditions share an inflammatory
response in a particular distribution pattern usually at a young age.
In most cases, a spontaneous stop of disease activity occurs with
limited recurrences during adult life. Lichen striatus has the
additional similarity of leaving hypopigmented skin areas which
can resolve spontaneously (84). Linear morphea usually presents as
a broad linear band of induration with often additional
dyspigmentation (both hyper- and hypopigmentation) (85).
However, the underlying genetic mutations have currently
not been discovered despite several research projects that haveFrontiers in Immunology | www.frontiersin.org 5been initiated. This is mainly due to the fact that melanocytes of
the inflammatory border of vitiligo are difficult to isolate and
proliferate in the lab probably because of their compromised skin
environment. Altered E-cadherin expression in SV melanocytes
may be a primary deficiency which could be one of the initiating
factors of SV hampering the in vitro culture of SV melanocytes
(86). As the distribution patterns in the face and the trunk have
been mapped in detail, future projects could focus on analyzing
skin areas that are not (yet) affected but are likely to contain
genetically identical melanocytes. Early SV rarely involves the
whole skin area which is supposed to be populated by
melanocytes originating from the same melanocyte precursor
and often leaves skipped areas of normally pigmented skin.
Based on the published case reports, the co-occurrence of
(localized) morphea and SV is striking. Although morphea has
also been associated with NSV, linear morphea seems particularly
linked to SV. Linear morphea follows Blaschko’s lines and genetic
mosaicism is therefore believed to be the underlying cause (87). The
distribution patterns of SV and linear morphea are clearly different
which can be explained by the different skin cell types which are
likely responsible for these conditions (melanocytes vs keratinocytes
or fibroblasts) (Figure 1). Both morphea and SV have been linked
to traumata or local enhanced immune responses and therefore one
autoimmune condition can elicit the other. It is remarkable that 2
mosaic disorders affecting cell types of different embryogenic origins
have a tendency to co-occur in the same body area. Despite some
case reports, this phenomenon remains however extremely rare and
the differential diagnosis with hypopigmented lesions caused be
morphea can be challenging (85).
In conclusion, SV research merits new attention as it may
provide interesting data for the pathogenesis and treatment of
vitiligo in general. To date, evidence points to a temporary
cytotoxic-response targeting mosaic melanocytes. Associated
autoimmune diseases are less prevalent compared to NSV,
although a remarkable overrepresentation of case reports with
(linear) morphea is present. A genetic predisposition (e.g. family
history of NSV) may enhance the chance of SV and the
subsequent development of halo naevi and NSV. Screening for
thyroid disease is less valuable in SV compared to NSV.AUTHOR CONTRIBUTIONS
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